Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy with interleukin 2 after ABMT in AML

M D Hamon1, H G Prentice, D J Gottlieb

  • 1Department of Haematology, Royal Free Hospital and School of Medicine, London, UK.

Bone Marrow Transplantation
|May 1, 1993
PubMed
Summary

Immunotherapy after autologous bone marrow transplant (ABMT) for acute myeloid leukemia (AML) in remission is safe and may reduce relapse rates. This approach, when initiated with adequate platelet counts, shows promising disease-free survival in AML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidrug Resistance in Acute Leukaemia: A Comparative Study of Immunocytochemical and RNA Slot Blot Detection of P-glycoprotein Expression.

Leukemia & lymphoma·2016
Same author

Understanding the Graft-Versus-Leukaemia Reaction.

Hematology (Amsterdam, Netherlands)·2016
Same author

Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study.

Molecular psychiatry·2014
Same author

Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients.

Internal medicine journal·2014
Same author

A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia.

Cytometry. Part B, Clinical cytometry·2013

Area of Science:

  • Hematology
  • Immunotherapy
  • Oncology

Background:

  • Acute myeloid leukemia (AML) is a significant hematologic malignancy.
  • Allogeneic bone marrow transplantation (BMT) is a curative option for AML.
  • Consolidation therapy aims to eliminate residual leukemia cells and prevent relapse.

Purpose of the Study:

  • To evaluate the safety and efficacy of immunotherapy following autologous bone marrow transplantation (ABMT) in AML patients in first remission.
  • To assess the impact of interleukin-2 (IL-2) immunotherapy on relapse rates and disease-free survival after ABMT.

Main Methods:

  • 18 patients with AML in first remission received myeloablative chemotherapy (+/- radio) followed by ABMT.
  • Seven patients received subsequent intravenous IL-2 immunotherapy.

Related Experiment Videos

  • Treatment with IL-2 was initiated after platelet count reached 30 x 10(9)/l to mitigate capillary leak syndrome.

    • Main Results:

    • The immunotherapy group (n=7) showed a 17% actuarial relapse risk and 71% disease-free survival at a median follow-up of 32 months.
    • A historical control group (n=11) receiving ABMT without immunotherapy had a 54% actuarial relapse risk and 36% disease-free survival at a median follow-up of 29 months.
    • Hypotension was the main side effect, managed with colloid infusion; one patient experienced fatal pulmonary edema due to capillary leak syndrome when IL-2 was initiated too early.

    Conclusions:

    • Immunotherapy, specifically IL-2, administered after ABMT in AML patients in first remission is safe when initiated with adequate platelet counts (>30 x 10(9)/l).
    • This immunotherapy approach may create an immunological environment that eliminates residual leukemia, leading to improved disease-free survival.
    • The findings suggest a potential benefit of immunotherapy in reducing relapse risk in AML post-ABMT.